© Reuters.
NEW YORK – Delcath Systems, Inc. (NASDAQ:DCTH), a company specializing in interventional oncology, has introduced a Healthcare Setting Locator on its website for identifying treatment sites for HEPZATO KIT, a liver-directed therapy for metastatic uveal melanoma (mUM). The Locator is designed to help patients, caregivers, and healthcare providers find healthcare settings that offer this treatment for mUM patients with specific liver involvement.
The Locator includes sites that are currently accepting patient inquiries and are equipped or in the process of being equipped to administer the HEPZATO KIT after completing necessary training and approvals. Kevin Muir, Delcath’s General Manager of U.S. Interventional Oncology, emphasized the tool’s importance in aiding those seeking treatment options.
Melody Burchett, President of A Cure In Sight, an advocacy group for Uveal Melanoma patients, praised the Locator for empowering patients to find and coordinate their own care, expanding their options beyond what may be available locally.
The HEPZATO KIT combines melphalan, a chemotherapeutic drug, with Delcath’s proprietary Hepatic Delivery System (HDS). This system allows high-dose chemotherapy to be delivered directly to the liver, while controlling systemic exposure to minimize side effects. The HEPZATO KIT is approved in the United States for adult patients with mUM who have unresectable hepatic metastases affecting less than 50% of the liver and limited extrahepatic disease that is treatable with resection or radiation.
Delcath Systems focuses on treatments for primary and metastatic liver cancers. Their products, including the HEPZATO KIT and CHEMOSAT Hepatic Delivery System for Melphalan, are designed to provide loco-regional delivery of high-dose chemotherapy to the liver.
This announcement is based on a press release statement from Delcath Systems, Inc. The company’s forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These statements are based on current expectations and speak only as of the date of their publication.
InvestingPro Insights
Delcath Systems, Inc. (NASDAQ:DCTH) has been proactive in enhancing patient accessibility to its HEPZATO KIT, but the company’s financial health and market performance are critical factors for potential investors and stakeholders to consider. Here’s a snapshot of the company’s current financial metrics and analyst insights from InvestingPro:
InvestingPro Data:
- Market Cap (Adjusted): $94.36M USD
- Revenue (last twelve months as of Q3 2023): $2.17M USD, with a notable decrease of 48.3%
- Gross Profit Margin (last twelve months as of Q3 2023): 67.62%
InvestingPro Tips:
1. Delcath Systems holds more cash than debt on its balance sheet, which can be a sign of financial stability in the short term.
2. Analysts do not anticipate the company will be profitable this year, and they have revised their earnings downwards for the upcoming period. This could be a concern for investors looking for short-term profitability.
For a deeper dive into Delcath Systems’ financials and future outlook, including additional InvestingPro Tips, visit https://www.investing.com/pro/DCTH. There are 11 additional tips available that could give you a comprehensive understanding of the company’s potential. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which will grant you access to exclusive insights and data to inform your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
